About me

John holds a tenured research and teaching appointment in the School of Pharmacy and Medical Science. He is Program Director of the Bachelor of Biomedical Research (Honours) program and a Course Coordinator in the Bachelor of Medical Science program.

John is a molecular and cellular immunologist with fundamental interests understanding the processes that control immunological tolerance and immunity in different animals, from the teleost fishes through to humans. He has a particular interest in innate immune recognition of endogenous and exogenous danger signals and how this integrates into normal and pathophysiological processes. He heads the Experimental Therapeutics Laboratory (Sansom Institute) and he directly supports 10 staff and 6... Read more

About me

John holds a tenured research and teaching appointment in the School of Pharmacy and Medical Science. He is Program Director of the Bachelor of Biomedical Research (Honours) program and a Course Coordinator in the Bachelor of Medical Science program.

John is a molecular and cellular immunologist with fundamental interests understanding the processes that control immunological tolerance and immunity in different animals, from the teleost fishes through to humans. He has a particular interest in innate immune recognition of endogenous and exogenous danger signals and how this integrates into normal and pathophysiological processes. He heads the Experimental Therapeutics Laboratory (Sansom Institute) and he directly supports 10 staff and 6 PhD students.

John has a strong track record of project grant funding awarded from a variety of sources including NHMRC and ARC and other national, state and institutional schemes. He has also a long history of highly successful industry engagement, including biotechnology consultancies, commercial research funding and funding from industry-leveraged federal government schemes including ARC Linkage and the Researches-in-Business (Enterprise Connect) schemes. Most recently, he has received over $5mil in research funding from emerging biotechnology company Sementis Ltd to develop from first principles a new viral vaccine vector platform for applications in infectious disease control, allergy and cancer immunotherapy. He has authored over 100 peer-reviewed publications and has a career h-index of 29.

Development of a potent new passive immunotherapeutic for the treatment and prevention of bacterial sepsis and septic shock, South Australian Health and Medical Research Institute, 01/01/2013 - 28/06/2015